Surgery Partners price target lowered to $38 from $49 at Citi

Citi analyst Jason Cassorla lowered the firm’s price target on Surgery Partners to $38 from $49 and keeps a Buy rating on the shares post the Q3 results. The analyst expects mix benefits from favorable physician adds will aid in the company’s margin expansion beyond cost efficiencies.